Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

NCT02520518 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Designed a new modified/simplified protocol see NCT 03180489

Conditions

Weight Loss

Interventions

DRUG: Dapagliflozin
DRUG: Placebo
BEHAVIORAL: Weight maintenance
BEHAVIORAL: Ad libitum dietary intake
BEHAVIORAL: Dietary restriction

Sponsor

Christopher Bell

Collaborators

[object Object]